A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2017
At a glance
- Drugs GEN 003 (Primary)
- Indications Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors Genocea Biosciences
- 08 Oct 2017 Primary endpoint (Long-term effect of GEN-003 on anogenital Herpes simplex virus type 2 (HSV-2) shedding) has been met as per the results presented at the IDWeek 2017.
- 08 Oct 2017 Results presented at the IDWeek 2017
- 19 Dec 2016 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.